Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.Jia, L., Simpson, R.D., Yuan, J., Xu, Z., Zhao, W., Cacatian, S., Tice, C.M., Guo, J., Ishchenko, A., Singh, S.B., Wu, Z., McKeever, B.M., Bukhtiyarov, Y., Johnson, J.A., Doe, C.P., Harrison, R.K., McGeehan, G.M., Dillard, L.W., Baldwin, J.J., Claremon, D.A.
(2011) ACS Med Chem Lett 2: 747-751
- PubMed: 24900262
- DOI: https://doi.org/10.1021/ml200137x
- Primary Citation of Related Structures:
- PubMed Abstract:
Structure guided optimization of a series of nonpeptidic alkyl amine renin inhibitors allowed the rational incorporation of additional polar functionality. Replacement of the cyclohexylmethyl group occupying the S1 pocket with a (R)-(tetrahydropyran-3-yl)methyl group and utilization of a different attachment point led to the identification of clinical candidate 9. This compound demonstrated excellent selectivity over related and unrelated off-targets, >15% oral bioavailability in three species, oral efficacy in a double transgenic rat model of hypertension, and good exposure in humans.
GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States.